Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing
progeny virus to infect nearby cells and repeat the process. We modified the oncolytic group …

Antiviral immune responses present a major hurdle to the efficacious use of oncolytic
adenoviruses as cancer treatments. Despite the existence of a highly immunosuppressive …

Effective immunotherapy of stromal-rich tumors requires simultaneous targeting of cancer
cells and immunosuppressive elements of the microenvironment. Here, we modified the …

Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection
for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to …

Simple Summary Oncolytic adenoviruses are engineered to selectively replicate in and
destroy cancer tissue. Moreover, these viruses are promising tools to restore antitumor …

Intravenous (iv) delivery of therapeutic viruses to human patients exposes virus particles to
the potentially neutralising environment of the human bloodstream, where many …

Oncolytic replication-selective adenoviruses constitute a rapidly growing therapeutic
platform for cancer. However, the role of the host immune response and the E3 …

Despite the rapid progress in the development of novel adoptive T-cell therapies, the clinical
benefits in treatment of established tumors have remained modest. Several immune evasion …

We show that a binary oncolytic/helper-dependent adenovirus (CAdVEC) that both lyses
tumor cells and locally expresses the proinflammatory cytokine IL-12 and PD-L1 blocking …

Purpose: The purpose of this study was to assess the impact of anti-adenovirus neutralizing
antibodies (AdNAbs) on the distribution, tolerability, and efficacy of intravenously …